Internal Medicine/Hematology & Oncology

 

Ellie Chan, MD

Assistant Clinical Professor

 

 

 

 

 

 

 

 

  Medical School: Institute of Medicine (1), Yangon, Myanmar
  Residency: University of Nevada School of Medicine, Las Vegas, NV
  Fellowship: Hematology & Oncology, University of Florida, Gainesville, FL
  Board Certified: American Board of Internal Medicine, Internal Medicine
  Awards and Recognition:

2013                Certificate, Advanced Postgraduate Program in Clinical Investigation
2011-2013      Scholar, Advanced Postgraduate Program in Clinical Investigation
                          Clinical and Translational Science Institute, University of Florida
2010                Second place, EKG competition University of Nevada School of Medicine
2007                Best PGY-1, University of Nevada School of Medicine
2002                Honors student in Pediatrics, Institute of Medicine (1), Yangon
2001                Honors student in Forensic medicine, Institute of Medicine (1), Yangon

     
  Publications (since 2009):

Chan F, Goodman O, Fink L, Vogelzang NJ, Pomerantz D, Khoury JD. Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostate.  Arch Pathol Lab Med. 2010 Jan;134(1):120-3.  PMID:  20073615


Khoury JD, Adcock DM, Chan F, Symanowski JT, Tiefenbacher S, Goodman O, Paz L, Ma Y, Ward DC, Vogelzang NJ, Fink LM..  Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer.  Am J Clin Pathol. 2010 Dec;134(6):964-9.  PMID:  21088161


Simone CG, Zuluaga Toro T, Chan E, Feely MM, Trevino JG, George TJ Jr.  Characteristics and outcomes of adenosquamous carcinoma of the pancreas.  Gastrointest Cancer Res.  2013 May;6(3):75-9.  PMID:  23936547

 


Books and Chapters


2012 Santos N, Wenger JB, Gupta E, Chan E, Peicher K, Jiang M, Liu Y, Havre P, Dahm P, Su L, Dang NH, Luesch H, Dang LH, University of Florida, Department of Medicine, Gainesville, Florida, USA. Can We Develop More Effective Combination Antiangiogenic Therapy for Patients with Cancer?  Nova Science Publishers; Horizons in Cancer Research, vol. 49, chapter 3, pp 65-96.


2013 Chan E and George TJ, Jr.  Gastric Cancer.  The Bethesda Handbook of Clinical Oncology, Fourth Edition.

 

 

Other Publications

 

 

Chan F, Samlowski EE and Samlowski WE.  Temsirolimus: a review of its use in the treatment of advanced renal cell carcinoma.  Clinical Medicine: Therapeutics 2009:1 167-174.


E. Chan, A. Alkhasawneh, L. Vila Duckworth,  T. Zuluaga Toro, H. Yan, W. Hou, S. J. Hughes, TJ. George. Prognostic significance of HER2 expression and associated clinical characteristics in Esophageal Adenocarcinoma.  J Clin Oncol 30: 2012 (suppl 34; abstr 114).


E. Chan, A. Ivey, L. H. Dang, K. Daily, W. Hou, D. Lynn Viviano, S. Watson, R. Granicz, M. McEwan, H. Yan, C. J. Allegra, T. J. George. Correlation of capecitabine associated hand-foot syndrome (HFS) and objective tumor response in patients with metastatic colorectal cancer (mCRC) treated with sorafenib and capecitabine (SorCape).  J Clin Oncol 30: 2012 (suppl 34; abstr 568).


Simon C, Zuluaga Toro T, Chan E, George TJ.  Characteristics and Outcomes of Adenosquamous Carcinoma of the Pancreas (manuscript in preparation).


E. Chan, A. Alkhasawneh, L. Vila Duckworth, T.  Zuluaga Toro, X. Lu, S. J Hughes, T. J. George.  EGFR family and cMet expression profiles and prognostic significance in Esophagogastric Adenocarcinoma.  J Clin Oncol 31, 2013 (suppl; abstr e15108).


E. Chan, A. Alkhasawneh, L. Vila Duckworth, T.  Zuluaga Toro, X. Lu, B. King, S. J. Hughes, T. J. George.  HER-2 expression and response to neoadjuvant chemoradiotherapy in Esophagogastric Adenocarcinoma.  J Clin Oncol 31, 2013 (suppl; abstr e15145).


Chan E, Alkhasawneh A, Duckworth LV, Toro TZ, Lu X, Hughes SJ, George TJ; University of California San Francisco, Fresno Medical Education Program, Fresno, CA; University of Florida, Gainesville, FL.  Expression relationships among EGFR family members and c-Met in esophagogastric adenocarcinoma.  J Clin Oncol 32, 2014 (suppl 3; abstr 75)


Chan E, Duckworth LV, Alkhasawneh A, Toro TZ, Lu X, Ben-David K, Hughes SJ, Rossidis G, Zlotecki R, Lightsey J, Daily K, Dang L, Allegra C, King B, George TJ.  HER-2 expression and response to chemoradiotherapy in Esophagogastric Adenocarcinoma. (Submitted)